late-stage assessment Draft guidance Health technology evaluation 21 January 2025 Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback